Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Healthcare picks: After CPH, I pick Viemed (VMD)

<< Previous

Bullboard Posts

Next >>

Comment by stockfyon Aug 29, 2021 11:02am

227 Views

Post# 33779384

RE:RE:Healthcare picks: After CPH, I pick Viemed (VMD)

With CPH at C$2.23, does Justin Keywood still have a job in Stifel?

stockfy wrote:

Does Justin Keywood still have a job in Stifel?

stockfy wrote:

Unlike many investors including the clueless analyst from Stifel Justin Keywood, I was very bullish on CPH at C$0.80 and C$0.90 just a few months ago and I also posted facts on this board why I was bullish on CPH at those price levels. These facts and reasons were from CPH's press releases and reports. Zero speculation. CPH is at C$1.55 now.

My new pick from the healthcare sector is Viemed Healthcare (VMD) now at C$9.

VMD has a pristine balance sheet and is dirt cheap now at C$9 trading just 7 times its 2021 adj. EBITDA and 1.5 times its 2021 revenue.

VMD also has many catalysts ahead including many growth initiatives, both organic and inorganic. These are facts. Read the latest Conference Call to see these facts and growth initiatives. The CC is posted on Seeking Alpha.